Skip to main content

Table 1 Baseline characteristics

From: Preoperative genetic testing impacts surgical decision making in BRCA mutation carriers with breast cancer: a retrospective cohort analysis

 

Total (n = 220)

BRCA results known prior to surgery (n = 113)

BRCA results known after surgery (n = 107)

p-value

Age at diagnosis

 Mean age (years)

47.3

45.7

49.1

<0.05

 Range (years)

22.3 – 81.7

22.3 – 79.1

26.0 – 81.7

 

 Median age (years)

46.4

44.0

47.6

<0.05

Race

 Caucasian

189 (85.9%)

97 (85.8%)

92 (86.0%)

NS

 African American

14 (6.4%)

8 (7.1%)

6 (5.6%)

NS

 Other

3 (1.4%)

2 (1.8%)

1 (0.9%)

NS

 Unknown

14 (6.4%)

6 (5.3%)

8 (7.5%)

NS

Laterality

 Unilateral

208 (94.5%)

106 (93.8%)

10. (95.3%)

NS

 Bilateral

12 (5.5%)

7 (6.2%)

5 (4.7%)

NS

Histology

 DCIS

24 (10.9%)

12 (10.6%)

12 (11.2%)

NS

 IDC

181 (82.3%)

93 (82.3%)

88 (82.2%)

NS

 ILC

13 (5.9%)

6 (5.3%)

7 (6.5%)

NS

 Other

2 (0.9%)

2 (1.8%)

0 (0.0%)

NS

Grade

 Grade 1

13 (5.9%)

7 (6.2%)

6 (5.6%)

NS

 Grade 2

58 (26.4%)

35 (31.0%)

23 (21.5%)

NS

 Grade 3

140 (63.6%)

68 (60.2%)

72 (67.3%)

NS

 Unknown

9 (4.1%)

3 (2.7%)

6 (5.6%)

NS

Tumor Size

 Mean size (mm)

27.02

30.80

22.95

<0.05

 Median size (mm)

19.5

22.00

18.00

<0.05

ER status

 Negative

104 (47.3%)

51 (45.1%)

53 (49.5%)

NS

 Positive

113 (51.4%)

62 (54.9%)

51 (47.7%)

NS

 Unknown

3 (1.4%)

0 (0.0%)

3 (2.8%)

NS

PR status

 Negative

133 (60.5%)

67 (59.3%)

66 (61.7%)

NS

 Positive

84 (38.2%)

46 (40.7%)

38 (35.5%)

NS

 Unknown

3 (1.4%)

0 (0.0%)

3 (2.8%)

NS

HER-2 Status

 Negative

158 (71.8%)

89 (78.8%)

69 (64.5%)

<0.05

 Positive

14 (6.4%)

11 (9.7%)

3 (2.8%)

<0.05

 Not performed or unknown

48 (21.8%)

13 (11.5%)

35 (32.7%)

<0.05

Triple negative breast cancer

 Yes

80 (36.4%)

43 (38.1%)

37 (34.6%)

NS

 No

92 (41.8%)

57 (50.4%)

35 (32.7%)

<0.05

 Unknown

48 (21.8%)

13 (11.5%)

35 (32.7%)

<0.05

T- Stage

 Tis

24 (10.9%)

12 (10.6%)

12 (11.2%)

NS

 T1

101 (45.9%)

46 (40.7%)

55 (51.4%)

NS

 T2

66 (30.0%)

38 (33.6%)

28 (26.2%)

NS

 T3

23 (10.5%)

12 (10.6%)

11 (10.3%)

NS

 T4

6 (2.7%)

5 (4.4%)

1 (0.9%)

NS

N-Stage

 N0

133 (60.5%)

67 (59.3%)

66 (61.7%)

NS

 N1

69 (31.4%)

32 (28.3%)

37 (34.6%)

NS

 N2

15 (6.8%)

12 (10.6%)

3 (2.8%)

<0.05

 N3

3 (1.4%)

2 (1.8%)

1 (0.9%)

NS

Overall TNM Stage

 Stage 0 (In-situ)

24 (10.9%)

12 (10.6%)

12 (11.2%)

NS

 Stage I

79 (35.9%)

37 (32.7%)

42 (39.3%)

NS

 Stage II

83 (37.7%)

42 (37.2%)

41 (38.3%)

NS

 Stage III

34 (15.5%)

22 (19.5%)

12 (112.2%)

NS

Adjuvant radiation

 Yes

104 (47.3%)

42 (37.2%)

62 (57.9%)

<0.05

 No

116 (52.7%)

71 (62.8%)

45 (42.1%)

<0.05

Chemotherapy

 None

71 (32.3%)

31 (27.4%)

40 (37.4%)

NS

 Neoadjuvant chemotherapy

49 (22.3%)

43 (38.1%)

6 (5.6%)

<0.05

 Adjuvant chemotherapy

100 (45.4%)

39 (34.5%)

61 (57.0%)

<0.05

BRCA1/2 results

 BRCA1 mutation

111 (50.5%)

56 (49.6%)

55 (51.4%)

NS

 BRCA2 mutation

109 (49.5%)

57 (50.4%)

52 (48.6%)

NS

  1. NS Not significant